However, single-agent checkpoint inhibitors that alter immune suppressive signals in other human cancer such as CTLA-4, PD-1 and its ligand PD-L1, have failed to demonstrated objective response when given as single agents to PDA patients [113]. This evidence concerns the gene CTLA4 and Patent ductus arteriosus.